Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (NASDAQ: TERN) is a clinical-stage biopharmaceutical company advancing novel small molecule therapies for liver diseases, oncology, obesity, and hematologic disorders. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on TERN-701 (chronic myeloid leukemia therapy), metabolic disorder candidates, and regulatory milestones. Our curated news collection includes:
• Clinical trial progress reports
• FDA submission updates
• Research partnership announcements
• Financial results disclosures
All content is sourced directly from company filings and verified press releases. Bookmark this page to monitor Terns' innovative work in molecularly-targeted therapies and capital-efficient drug development.
Terns Pharmaceuticals (TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for oncology and obesity, has announced equity inducement grants to two new employees. The grants, approved under the 2022 Employment Inducement Award Plan and Nasdaq Listing Rule 5635(c)(4), consist of options to purchase 611,000 shares of Terns common stock.
The stock options come with a 10-year term and an exercise price of $2.56 per share, matching Terns' closing stock price on April 1, 2025. These options will vest over a four-year period, contingent on continued employment through the vesting dates.
Terns Pharmaceuticals (TERN) has reported its Q4 and full year 2024 financial results, highlighting significant clinical progress in its pipeline. The company ended 2024 with $358.2 million in cash and equivalents, providing runway into 2028.
Key developments include:
- Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) completed dose escalation, with dose expansion expected in Q2 2025
- First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity, with 12-week data expected in Q4 2025
- TERN-601 demonstrated weight loss up to 5.5% over 28 days in Phase 1 trials
Financial results show R&D expenses of $70.1 million for 2024 (up from $63.5 million in 2023), G&A expenses of $31.8 million (down from $39.1 million in 2023), and a net loss of $88.9 million (improved from $90.2 million in 2023).
Terns Pharmaceuticals (Nasdaq: TERN) has granted an equity inducement award to its new Chief Financial Officer, Andrew Gengos, as announced on February 26, 2025. The award, approved under the 2022 Employment Inducement Award Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), consists of an option to purchase 750,000 shares of Terns common stock.
The stock option features a 10-year term with an exercise price of $3.73 per share, matching Terns' closing stock price on February 24, 2025. The option will vest over a four-year period, contingent upon Mr. Gengos maintaining his employment with the company.
Terns Pharmaceuticals (TERN) has provided program updates across its development pipeline and announced participation at the TD Cowen 45th Annual Healthcare Conference. The company reported strong progress with its TERN-701 CARDINAL study for chronic myeloid leukemia (CML), with dose expansion expected to begin in Q2 2025 and additional data in Q4 2025. New data shows TERN-701 has an improved drug-drug interaction profile compared to asciminib.
For its obesity program, Terns introduced the Phase 2 FALCON study design for TERN-601, an oral GLP-1 receptor agonist, scheduled to begin in early Q2 2025 with 12-week data expected in 2H 2025. The company aims to achieve competitive weight loss with best-in-class tolerability without complicated dose titrations.
Terns continues evaluating opportunities for TERN-501 in metabolic diseases and is advancing its TERN-800 series of GIPR modulators for obesity. With $372.8 million in cash as of September 30, 2024, the company expects runway into 2028.
Terns Pharmaceuticals (Nasdaq: TERN) has appointed Andrew Gengos as Chief Financial Officer, effective immediately. Gengos brings 25 years of leadership experience in biotech and life sciences to the clinical-stage biopharmaceutical company.
Gengos most recently served as CFO of Athira Pharma and previously as Chief Business Officer at Cyteir Therapeutics, where he led the company's IPO finance team. His experience includes CEO roles at ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals, and eight years as VP of Strategy and Corporate Development at Amgen.
The appointment comes as Terns, which focuses on developing small-molecule product candidates for oncology and obesity, anticipates clinical readouts later this year. Gengos holds an MBA from UCLA Anderson School of Management and a BS in Chemical Engineering from MIT.
Terns Pharmaceuticals (Nasdaq: TERN) has appointed Robert Azelby to its Board of Directors, while Carl Gordon steps down after seven years of service. Azelby brings 25 years of biotechnology expertise, particularly in strategic, operational, and commercial leadership.
Azelby's extensive experience includes serving as CEO of Eliem Therapeutics (2020-2023) and Alder BioPharmaceuticals (2018-2019), as well as executive positions at Juno Therapeutics and Amgen. His appointment comes as Terns prepares TERN-701 for late-stage studies in chronic myeloid leukemia.
Currently, Azelby serves on the boards of ADC Therapeutics, Autolus Therapeutics, and Cardinal Health. He holds a B.A. in Economics and Religious Studies from the University of Virginia and an M.B.A. from Harvard Business School.
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for serious diseases including oncology and obesity, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The company's senior management will deliver a presentation on Wednesday, February 12, 2025, at 4:00 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the investor relations page at http://ir.ternspharma.com. The presentation recording will remain available on the company's website for a minimum of 30 days following the event.
Terns Pharmaceuticals (Nasdaq: TERN) announced the grant of equity inducement awards to a new employee under its 2022 Employment Inducement Award Plan. The company granted stock options to purchase 250,000 shares at an exercise price of $4.46 per share, which was the closing price on January 31, 2025. The options have a 10-year term and vest over four years, contingent on continued employment. The grant was approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4) and serves as a material inducement for the employee's acceptance of employment.
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases including oncology and obesity, has announced its upcoming participation at the 43rd Annual J.P. Morgan Healthcare Conference.
The company's management will deliver their presentation on January 15th, 2025, at 4:30 p.m. PT. Investors and interested parties can access a live webcast of the presentation through the investor relations page at http://ir.ternspharma.com. The presentation recording will remain available on the company's website for a minimum of 30 days following the event.
Terns Pharmaceuticals (Nasdaq: TERN) announced the granting of equity inducement awards to a new employee under its 2022 Employment Inducement Award Plan. The grant, approved by the Company's Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4), includes options to purchase 9,000 shares of Terns common stock.
The options come with a 10-year term and an exercise price of $5.54 per share, matching Terns' closing stock price on December 31, 2024. The options will vest over a four-year period, contingent on the employee's continued service with the company.
